



1803-02: Prevacept Infection Control, inc - PrevaCept Lock Solution

Evaluated by the Rapid Review panel (RRP)
22 August 2018

Evaluation Level E5: Evidence presented does not demonstrate that the product is more efficient or efficacious at improving infection prevention and control interventions to reduce healthcare associated infections than other available products currently in use.

Prevacept Infection Control, Inc has developed PrevaCept Lock Solution, a microbiocidal catheter lock solution containing the antibiotic trimethoprim and ethanol in a phosphate buffered saline solution. The product is instilled into the lumen of central venous catheters when the catheter is not in use to:

- kill pathogenic microbes within the catheter lumen and reduce the risk of central line associated bloodstream infections
- provide a physical barrier to prevent the retrograde flow of blood into the catheter lumen to maintain patency

Evaluation Disclaimer: The RRP does not formally review cost-effectiveness or implementation barriers during its evaluation of products; these factors may be considered in a separate process. It is the responsibility of the applicant to carry out any further required development, including trials, cost-effectiveness assessments or product implementation within the NHS. All statements comparing the efficiency or efficacy of products are in the context of products available for use to the NHS at the date of evaluation.